Startups to Watch
From therapeutics to diagnostics, these 10 startups are creating technologies aimed at combating the rise of antibiotic resistant bacterias.
In 2013, the Centers for Disease Control published a report on the state of antibiotic resistant bacteria. The report concluded that “antibiotic resistance is one of the biggest public health challenges of our time.” As a result, a number of healthcare-focused startups are now working to combat the rise of superbugs in new ways.
With enough exposure, any type of bacteria can adapt and eventually become resistant to a specific set of antibiotics. This can create major complications when treating infectious diseases.
Among the most problematic types of bacteria are Clostridioides difficile (or C. diff), Carbapenem-resistant Enterobacteriaceae (CRE), and Neisseria gonorrhoeae.
Using CB Insights data, we’ve identified 10 notable startups in the superbug resistance space. Startups on our list are building AI-powered drug discovery platforms, new vaccines, medication management programs, and diagnostics tools, among other solutions.
We selected the below companies based on their Mosaic score — CB Insights’ algorithm that uses financial and non-financial signals to predict private company health — as well as the recency and size of their disclosed funding. They are listed in descending order of total disclosed funding.
Want the full expert post? Become a CB Insights customer.
If you’re already a customer, log in here.
